Ruth Puig-Peiro
Publications and Insights
- Insight: Pharmacogenomics Testing: A Crucial Piece to Unlocking the Full Value of Medicines
- Insight: Infectious disease: another reason to try Veganuary for the NHS
- Publication: A Framework for Value-aligned Pricing of Combination Therapies
- Insight: Around the World in HTAs: United States – Making HTA Great Again
- Publication: Socio-Economic Value of Adult Immunisation Programmes
- Publication: Developing a Conceptual Framework of Healthcare System Pressure
- Publication: The Socioeconomic Burden Of Cervical Cancer in the UK: What are the benefits of achieving the WHO elimination target?
- Insight: Could Plant-based Diets Transform Health Care Spending?
- Publication: Innovation for Health System Efficiency and Improvement
- Publication: Reimagining Prevention for a Healthier, More Prosperous Society
- Publication: The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe
- Insight: Improving the Measurement of Valued Output in Primary Care in England
- Insight: Sleepio: Lessons from the Frontier of Digital Therapeutics
- Insight: To Hell with the 3L! NICE’s Missed Opportunity to Upgrade Health Outcome Measurement
- Publication: Payment Models for Multi-Indication Therapies
- Publication: The Value of Vaccines in Maintaining Health System Capacity in England
- Publication: How is Quality of Life Measured for Health Technology Assessments?
- Publication: Realising The Broader Value of Vaccines in the UK: Ready for Prime Time?
- Publication: Drop Dead: Is Anchoring at ‘Dead’ a Theoretical Requirement in Health State Valuation?
- Publication: The BRAVE Initiative: The BRAVE Narrative for Broad Recognition of Value in Vaccines Engagement
- Publication: Realising the Broader Value of Vaccines in the UK
- Publication: HTA and Payment Mechanisms for New Drugs to Tackle AMR
- Publication: How Should We Measure Quality of Life Impact in Rare Disease? Recent Learnings in Spinal Muscular Atrophy
- Publication: Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward
- Publication: The Impact of New Medicines in the NHS: 70 Years of Innovation
- Publication: R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C
- Publication: Barriers to Uptake of Minimal Access Surgery in the United Kingdom
- Publication: Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help?
- Publication: Projecting Expenditure on Medicines in the NHS: Second Edition
- Publication: Projecting Expenditure on Medicines in the NHS
- Publication: International Comparisons of Medicines Prices: 2011 Indices
- Publication: The Use of Pay-for-Performance for Drugs: Can It Improve Incentives for Innovation?
- Publication: Time Trends in NICE HTA Decisions
- Publication: Researching the Relative Efficacy and Relative Effectiveness of Medicines across Europe